⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822519 | 0.78 | — | — | |
| SCHEMBL1470657 | 0.75 | — | — | |
| SCHEMBL6057337 | 0.72 | — | — | |
| SCHEMBL845123 | 0.69 | — | — | |
| SCHEMBL5579 | 0.69 | — | — | |
| SCHEMBL6852459 | 0.68 | ALDH1A1 (0.36) | — | |
| SCHEMBL736944 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL1958678 | 0.67 | — | — | |
| SCHEMBL514355 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL866238 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038462-A2 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| US-11376241-B2 | Aryl hydrocarbon receptor (AhR) modulator compounds | PHENEX PHARMACEUTICALS AG (DE) | 2022-07-05 | — | — | US | disclosed |
| CN-110248940-B | Aryl hydrocarbon receptor (AhR) modulator compounds | 菲尼克斯药品股份公司 | 2022-07-01 | — | — | CN | disclosed |
| US-20220089597-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2022-03-24 | — | — | US | disclosed |
| US-20210309663-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2021-10-07 | — | — | US | disclosed |
| US-10981908-B2 | Aryl hydrocarbon receptor (AHR) modulator compounds | PHENEX PHARMACEUTICALS AG (DE) | 2021-04-20 | — | — | US | disclosed |
| US-10975080-B2 | Compounds and compositions for inhibiting the activity of SHP2 | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| EP-3577112-B1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2020-12-30 | — | — | EP | disclosed |
| EP-3577115-B1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2020-12-02 | — | — | EP | disclosed |
| US-20190185475-A1 | COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2 | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-06-20 | — | — | US | disclosed |
| WO-2018141857-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2018-08-09 | — | — | WO | disclosed |
| EP-3310779-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203404-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| EP-1799694-B1 | METHOD OF PRODUCING SILYLALKOXYMETHYL HALIDE | DOW CORNING TORAY CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-7915439-B2 | Method of producing silylalkoxymethyl halide | DOW CORNING TORAY COMPANY, LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7679884-B2 | Organosilicon phosphorus-based electrolytes | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-20100029970-A1 | Organosilicon Phosphorus-Based Electrolytes | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2010-02-04 | — | — | US | disclosed |
| US-20090203932-A1 | Method of Producing Silylalkoxymethyl Halide | DOW CORNING TORAY CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1799694-A1 | METHOD OF PRODUCING SILYLALKOXYMETHYL HALIDE | Dow Corning Toray Co., Ltd. (JP) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006040964-A1 | METHOD OF PRODUCING SILYLALKOXYMETHYL HALIDE | DOW CORNING TORAY CO., LTD. (JP) | 2006-04-20 | — | — | WO | disclosed |